Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

OBJECTIVE: To investigate the rate of decline in forced vital capacity (FVC), and the effect of nintedanib on the rate of decline in FVC, in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who had risk factors for rapid decline in FVC. METHODS: The SENSCIS trial enrolled subjects with SSc and fibrotic ILD of

• Khanna, D.
• Maher, T. M.
• Volkmann, E. R.
• Allanore, Y.
• Smith, V.
• Assassi, S.
• Kreuter, M.
• Hoffmann-Vold, A. M.
• Kuwana, M.
• Stock, C.
• Alves, M.
• Sambevski, S.
• Denton, C. P.